US Patent Issued to NEURIM PHARMACEUTICALS (1991) on Sept. 15 for "Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus" (Israeli Inventors)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,735,747, issued on Sept. 15, was assigned to NEURIM PHARMACEUTICALS (1991) LTD. (Tel Aviv, Israel).

"Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus" was invented by Nava Zisapel (Tel Aviv, Israel) and Moshe Laudon (Tel Aviv, Israel).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods and products for identifying individuals who are likely to respond in a positive (benefit) or negative (harm) manner to a pharmacological drug treatment intended for treating or preventing a neuropsychiatric disorder, neurodegeneration, sleep-wake cycles such including and not limited to...